community-acquired pneumonia
Conditions
Interventions
MXHQ standard-dose group:On the basis of the oral treatment with moxifloxacin tablets (400 mg once daily), a standard dose of MXHQ granules were given for treatment, completely dissolved in warm boil
MXHQ low-dose group:On the basis of the oral treatment with moxifloxacin tablets (400 mg once daily), a low dose of MXHQ granules were given for treatment(70% conversion of standard dose), completely
MXHQ placebo group:On the basis of the oral treatment with moxifloxacin tablets (400 mg once daily), MXHQ placebo granules were given for treatment, the color, taste and appearance of placebo granules
Sponsors
Guangdong Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Fulfillment of western medical diagnostic criteria for community-acquired pneumonia infection; (2) Aged between 18 and 75 years, no gender limitation; (4) Those who voluntarily signed an informed consent form, and the process of obtaining informed consent (3) First visit without treatment; should be in accordance with GCP.
Exclusion criteria
Exclusion criteria: 1.Patients with severe CAP. 2.A significant increase in the total number of blood lymphocytes is suspected in a person with viral infection. 3.Taking other antiviral drugs, antihistamines, antibiotics, etc. prior to the visit. 4.Have underlying lung disease (e.g., bronchiectasis, asthma, chronic obstructive pulmonary disease), tuberculosis, lung tumors, noninfectious interstitial lung disease, pulmonary edema, pulmonary atelectasis, pulmonary embolism, pulmonary eosinophilic infiltrates, and pulmonary vasculitis. 5.Autoimmune diseases, long-term immunosuppressive therapy, immunosuppressed patients (immunosuppressed patients i.e., those who have undergone organ/bone marrow/stem cell transplantation; chemotherapy within the past 30 days; neutropenia (neutrophils 30 days); congenital or acquired immunodeficiencies, e.g., HIV infection with a CD4 count of <350 cells/ml.). 7.Individuals with a definite allergic reaction to any of the drugs in this study. 8.Situations where there is a risk of coadministration with moxifloxacin tablets. Examples include patients taking antiepileptic drugs, non-steroidal anti-inflammatory drugs, antiarrhythmic drugs such as Class IA (quinidine, procainamide) and Class III (amiodarone, sotalol), warfarin or its derivatives. 9.Women during pregnancy, breastfeeding. 10.Persons with psychiatric disorders or severe disorders of consciousness or aphasia, who are unable to express themselves accurately. 11.Subjects who are participating in a clinical trial of another drug or who have participated in another clinical trial within the past 3 months. 12.Subjects judged by the investigator to be poorly adherent and unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical cure rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Days to disappearance of clinical symptom;Vital signs;Chest Imaging;Laboratory examination; | — |
Countries
China
Contacts
Public ContactPan Hudan
Guangdong Hospital of Traditional Chinese Medicine
Outcome results
None listed